Vicadrostat

Vicadrostat (BI 690517) is Boehringer Ingelheim's oral aldosterone synthase (CYP11B2) inhibitor in Phase 3 development across heart failure, chronic kidney disease, and high-risk cardiovascular disease - every Phase 3 trial pairs it with empagliflozin (Jardiance), BI/Lilly's SGLT2 inhibitor. The bet: aldosterone drives cardiorenal damage in patients already on SGLT2 inhibitors, and shutting off aldosterone production at the source is cleaner than blocking the receptor with spironolactone-class drugs. Three Phase 3 cardiovascular/heart failure trials are enrolling roughly 22,000 patients combined, with a Phase 2 CKD trial (n=492) wrapping up [1][2]. If the combination beats placebo on hard outcomes like cardiovascular death and heart failure events, BI gets label-expansion logic for Jardiance plus a new co-prescribed product in a market BI/Lilly already dominate. Readouts are 2027-2028 territory. The competitive question splits along mechanism: whether aldosterone synthase inhibitor (ASI) class rivals baxdrostat (AstraZeneca, Phase 3 in resistant hypertension) and lorundrostat (Mineralys, Phase 3 in hypertension with 2025 positive readouts) expand into cardiorenal outcomes before vicadrostat reads out, and separately whether vicadrostat plus empagliflozin beats the mechanism-adjacent mineralocorticoid receptor antagonist (MRA) finerenone (Bayer's Kerendia), already approved for diabetic CKD with cardiorenal outcomes data.

Novel compound, never approved. Currently in Phase 3 for three indications, all in combination with empagliflozin: EASi-PROTKT (NCT07064473) in 11,800 patients with type 2 diabetes, hypertension, and established cardiovascular disease; a heart failure with reduced ejection fraction (HFrEF) trial (NCT06935370) in 4,200 patients - HFrEF is the subset of heart failure where the heart pumps weakly, and where cardiorenal drugs have historically shown the clearest mechanistic benefit; and a broader heart failure trial (NCT06424288) in 6,000 patients [1][6]. Combined, that's nearly 22,000 patients across the cardiorenal axis - one of the largest Phase 3 programs in cardiometabolic disease right now. Phase 2 in CKD (NCT06926660) is active but not recruiting at 492 patients, with eGFR change at week 14-16 as primary endpoint, meaning a near-term readout [2]. No publicly disclosed FDA breakthrough or fast-track designations as of this writeup. Expected Phase 3 readouts fall in 2027-2028 based on enrollment timelines and event-driven endpoints, though BI hasn't given firm guidance. The Phase 2 CKD readout is the next major catalyst, and positive eGFR data would validate the combination thesis and lift the Phase 3 probability of success. Phase 1 PK/PD work confirms dose-dependent aldosterone suppression in healthy volunteers (Schulze et al. 2025) [3], and Phase 2 pharmacodynamic data in CKD patients (Gashaw et al. 2026) report selective aldosterone suppression with preserved cortisol response [4]. The compound has UNII AF4VW4GA3H and RxNorm CUI 2721362 in the NLM database.

Aldosterone is a hormone made by the adrenal glands that tells the kidneys to hold onto salt and water. In healthy people that maintains blood pressure and volume. In patients with heart failure, hypertension, and chronic kidney disease, aldosterone runs too high and drives the disease forward: blood pressure climbs, the heart muscle stiffens and scars, the kidneys lose filtration capacity. Existing drugs block the aldosterone receptor - spironolactone, eplerenone, and finerenone let the body make aldosterone but stop it from acting. These work but cause hyperkalemia (dangerous potassium buildup), and spironolactone hits sex hormone receptors causing gynecomastia. Vicadrostat blocks CYP11B2, the enzyme inside adrenal cells that converts a precursor steroid into aldosterone. No aldosterone made, no receptor activation needed, in theory less hyperkalemia because the upstream signal is gone. The hard biology problem: CYP11B2 looks almost identical to CYP11B1, the enzyme that makes cortisol - the body's main stress hormone. Hit CYP11B1 and you suppress cortisol, causing adrenal insufficiency. First-generation aldosterone synthase inhibitors like osilodrostat (LCI699) were so non-selective they got repurposed for Cushing's disease (where you want cortisol suppression). Vicadrostat is a second-generation compound designed for selectivity. Phase 1 data show dose-dependent aldosterone suppression with maintained cortisol response, with single and multiple doses ≤80 mg well tolerated [3], and Phase 2 work in CKD patients reports selective aldosterone suppression preserving cortisol [4]. The class shows consistent blood-pressure lowering in meta-analysis [5][7]. That selectivity claim is the core scientific bet - specific numerical cortisol suppression rates at therapeutic doses are not yet publicly disclosed at the granularity investors will want.

The headline trial is EASi-PROTKT (NCT07064473): randomized, double-blind, placebo-controlled in 11,800 patients with type 2 diabetes, hypertension, and established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) [1]. All patients are on empagliflozin background therapy; vicadrostat or placebo is added. Primary endpoint: time to first event of cardiovascular death or heart failure event (hospitalization or urgent visit). Event-driven, so trial length depends on how fast events accrue - typically 3-4 years for cardiometabolic outcomes trials at this size. Two other Phase 3 trials run in parallel: NCT06935370 in 4,200 HFrEF patients and NCT06424288 in 6,000 broader HF patients, both using a CV death plus HHF plus urgent HF visit composite [6]. Phase 2 in CKD (NCT06926660) uses absolute change in eGFR from baseline to week 14-16, a surrogate endpoint that supports CKD outcomes trial design if positive but doesn't approve a drug [2][4]. Trial design concern: requiring empagliflozin background means BI can't claim benefit over Jardiance alone, only as add-on. That's a labeling question, not a science question. Enrollment is active across all three Phase 3 trials; pace appears healthy based on BI's execution in EMPA-REG and EMPEROR. Comparator is placebo plus empagliflozin, not finerenone, which leaves the head-to-head against Bayer's Kerendia unanswered. Direct ASI class competitors are not yet in cardiorenal outcomes trials: baxdrostat (AstraZeneca) is in Phase 3 for resistant hypertension, and lorundrostat (Mineralys) reported positive Phase 3 results in 2025 in Launch-HTN and Advance-HTN with NDA filing planned for Q4 2025/Q1 2026 - but both are hypertension-first programs with no announced cardiovascular outcomes trials, so vicadrostat currently leads the class on outcomes trial scope.

This drug has a 55% estimated chance of eventually being approved. That starting point comes from the historical approval rate for Phase 3 drugs in this area, which is about 57%. The estimate goes up slightly because the trial enrolled more patients than typical, earlier-phase results were strong, and it tracks more secondary endpoints than usual - but it gets pulled back down by heavier-than-usual blinding. The remaining factors are close to average for this stage, so they don't move the number much.

Hyperkalemia is the headline safety risk. Suppress aldosterone, kidneys retain potassium - this dragged on spironolactone uptake in earlier outcomes trials where real-world hyperkalemia rates ran high. Finerenone's pitch was lower hyperkalemia than steroidal MRAs; vicadrostat needs to beat finerenone or at least match it. Cortisol selectivity is the second mechanism-based risk. CYP11B2 and CYP11B1 share ~93% sequence identity. Hit CYP11B1 and you suppress cortisol, causing adrenal insufficiency at scale. Osilodrostat's non-selectivity made it a Cushing's drug rather than a hypertension drug. Vicadrostat's Phase 1 and Phase 2 selectivity claims need to hold across thousands of patients on chronic dosing - long-tail safety issues often emerge only at Phase 3 scale [3][4]. Efficacy risk: the empagliflozin background means add-on benefit must be detectable above SGLT2 effects, which already cut CV death and HHF substantially (EMPEROR-Reduced, EMPA-REG OUTCOME). Smaller delta means harder statistical task. Commercial risk: finerenone (Kerendia, Bayer) is already approved for diabetic CKD with cardiorenal outcomes data (FIDELIO-DKD, FIGARO-DKD) and is growing fast - Q1 2025 sales hit €161M (+89% YoY), with full-year 2025 tracking well above €600M on annualized run rate [8]. Payers will ask why vicadrostat plus empagliflozin beats finerenone plus empagliflozin. Without head-to-head data, the answer is mechanism story and selectivity claim, which payers don't pay premium prices for. Execution risk: 22,000 patients across three Phase 3 trials is enormous surface area for safety signals. Class-rival timing risk: lorundrostat's NDA filing in late 2025/early 2026 [9] means an ASI may reach the US market for hypertension years ahead of vicadrostat, shaping payer perceptions of the class before vicadrostat's outcomes data arrive.

Worth watching. The signal worth waiting for is the Phase 2 CKD readout (NCT06926660, n=492), where eGFR change at week 14-16 will tell you whether the combination story holds [2][4]. If vicadrostat plus empagliflozin shows meaningful eGFR improvement beyond what empagliflozin alone delivers (well-characterized from EMPA-KIDNEY), the Phase 3 program gets a credibility boost and the 72% PoS looks conservative. If it's a wash or shows hyperkalemia trouble, the Phase 3 trials inherit a heavy headwind. Boehringer Ingelheim is private (no stock to trade), but commercial implications ripple to Eli Lilly (empagliflozin co-promote partner), Bayer (finerenone competitor; Kerendia Q1 2025 sales €161M, +89% YoY [8]), AstraZeneca (baxdrostat in resistant hypertension Phase 3), and Mineralys Therapeutics (lorundrostat, MLYS, Phase 3 hypertension positive, NDA filing late 2025/early 2026 [9]). Material patent overhang: empagliflozin's US patent landscape is contested, with composition coverage expiring 2025-2027 and method-of-use patents potentially extending exclusivity into the 2030s; 46 patent litigations are on file [10]. If generics enter before vicadrostat approval (2027-2028 window), the co-promotion premium with Lilly collapses - BI may be better positioned to own the combination alone at lower co-promote economics, but the commercial calculus shifts materially. BI's ~$25B revenue base gives them runway to push this program even if early signals are mixed. The strategic logic is sound: own SGLT2 inhibitor (Jardiance), add aldosterone synthase inhibitor, capture cardiorenal market across diabetes, HF, and CKD. Check back at the Phase 2 CKD readout - that's the inflection point. Watch for any BI investor day disclosure on vicadrostat selectivity or CKD Phase 2 timing.